Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.44B 2.18B 2.01B 1.82B 3.4B 231B 3.47B 23.91B 9.61B 122B 9.14B 8.95B 384B P/E 2026 *
-182x
P/E 2027 * 37.3x
Enterprise Value 2.44B 2.18B 2.01B 1.82B 3.4B 231B 3.47B 23.91B 9.61B 122B 9.14B 8.95B 384B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 1.8x
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week-0.36%
Current month-2.60%
1 month-4.66%
3 months-9.98%
6 months-13.66%
Current year-15.65%
1 week 39.53
Extreme 39.53
44.31
1 month 37.54
Extreme 37.54
44.31
Current year 37.54
Extreme 37.54
59.68
1 year 37.54
Extreme 37.54
59.68
3 years 23.04
Extreme 23.045
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 65 23/03/2015
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/8/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/8/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/8/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-0.36%-24.71%+77.93% 2.43B
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.70%+2.28%+40.53%+84.45% 417.93B
Weighted average by Cap. +1.28%+3.04%+53.31%+100.41%

Financials

2026 *2027 *
Net sales 884M 793M 730M 660M 1.24B 83.97B 1.26B 8.68B 3.49B 44.16B 3.32B 3.25B 139B 1.35B 1.21B 1.12B 1.01B 1.89B 129B 1.93B 13.29B 5.34B 67.64B 5.08B 4.98B 213B
Net income -8.1M -7.26M -6.68M -6.05M -11.31M -769M -11.52M -79.45M -31.92M -404M -30.38M -29.73M -1.28B 127M 114M 105M 94.86M 177M 12.06B 181M 1.25B 501M 6.34B 477M 467M 20.01B
Net Debt - -
Projected Income Statement - Annual - Supernus Pharmaceuticals, Inc.
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
30/10/26 US$41.94 +0.24% 2,818,857
29/10/26 US$41.84 +1.85% 1,885,193
28/10/26 US$41.08 +0.29% 1,099,364
27/10/26 US$40.96 +0.47% 1,075,468
26/10/26 US$40.77 +0.17% 930,903
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
41.94USD
Average target price
60.50USD
Spread / Average Target
+44.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Supernus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SUPN Stock